NCT07708714: Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 250 planned
- Started
- 13 May 2026
- Primary completion
- 30 Nov 2030
- Arms
- Hydroxyurea: Original NOHARM Cohort, Hydroxyurea: New Comparator Cohort
- Results
- None posted
- 13 May 2026: Trial started
- 16 Jul 2026: Trial registered